Associated Papers
Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E et al.
Cancer Gene Therapy, 2022
34045664 (PubMed )
Supplement: 41417_2021_347_MOESM4_ESM.xls › C000-2SXE39
Technological Advances: CEBPA and FLT3 Internal Tandem Duplication Mutations Can be Reliably Detected by Next Generation Sequencing.
Akabari R et al.
Genes, 2022
Germline mutations among Polish patients with acute myeloid leukemia.
Bąk A et al.
Hereditary Cancer in Clinical Practice, 2021
The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.
Konopka B et al.
Oncotarget, 2016
A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A et al.
The Journal of Molecular Diagnostics : Jmd, 2015
Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
Sarojam S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes.
Carmichael CL et al.
British Journal of Haematology, 2010
20456351 (PubMed )
Supplement: supplement_1.pdf
CCAAT/enhancer-binding protein alpha (CEBPA) polymorphisms and mutations in healthy individuals and in patients with peripheral artery disease, ischaemic heart disease and hyperlipidaemia.
Fuchs O et al.
Folia Biologica, 2010
Molecular study of CEBPA in familial hematological malignancies.
El Abed R et al.
Familial Cancer, 2009
Select a paper to view details